Pluristem Therapeutics (PSTI) Initiates S. Korean Sites in Phase II of PLX Cells as IC Treatment
Tweet Send to a Friend
Pluristem Therapeutics (Nasdaq: PSTI) announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
